Pantozol Control

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
25-05-2023
产品特点 产品特点 (SPC)
25-05-2023
公众评估报告 公众评估报告 (PAR)
02-05-2013

有效成分:

pantoprazole

可用日期:

Takeda GmbH

ATC代码:

A02BC02

INN(国际名称):

pantoprazole

治疗组:

Proton pump inhibitors

治疗领域:

Gastroesophageal Reflux

疗效迹象:

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

產品總結:

Revision: 17

授权状态:

Authorised

授权日期:

2009-06-11

资料单张

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PANTOZOL CONTROL 20 MG GASTRO-RESISTANT TABLETS
pantoprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist have told
you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse after 2 weeks.
-
You should not take PANTOZOL Control tablets for more than 4 weeks
without consulting a
doctor.
WHAT IS IN THIS LEAFLET
1.
What PANTOZOL Control is and what it is used for
2.
What you need to know before you take PANTOZOL Control
3.
How to take PANTOZOL Control
4.
Possible side effects
5.
How to store PANTOZOL Control
6.
Contents of the pack and other information
1.
WHAT PANTOZOL CONTROL IS AND WHAT IT IS USED FOR
PANTOZOL Control contains the active substance pantoprazole, which
blocks the ‘pump’ that
produces stomach acid. Hence it reduces the amount of acid in your
stomach.
PANTOZOL Control is used for the short-term treatment of reflux
symptoms (for example heartburn,
acid regurgitation) in adults.
Reflux is the backflow of acid from the stomach into the gullet
(“foodpipe”), which may become
inflamed and painful. This may cause you symptoms such as a painful
burning sensation in the chest
rising up to the throat (heartburn) and a sour taste in the mouth
(acid regurgitation).
You may experience relief from your acid reflux and heartburn symptoms
after just one day of
treatment with PANTOZOL Control, but this medicine is not meant to
bring immediate relief. It may
be necessary to take the tablets for 2-3 consecutive days to relieve
the symptoms.
_ _
You must talk to a doctor if you do not feel bet
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PANTOZOL Control 20 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium
sesquihydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet.
Yellow, oval, biconvex film-coated tablets imprinted with “P20” in
brown ink on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PANTOZOL Control is indicated for short-term treatment of reflux
symptoms (e.g. heartburn, acid
regurgitation) in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to
achieve improvement of
symptoms. Once complete relief of symptoms has occurred, treatment
should be discontinued.
The treatment should not exceed 4 weeks without consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous
treatment, the patient should be
instructed to consult a doctor.
Special populations
No dose adjustment is necessary in elderly patients or in those with
impaired renal or liver function.
_ _
_Paediatric population _
_ _
PANTOZOL Control is not recommended for use in children and
adolescents below 18 years of age
due to insufficient data on safety and efficacy.
Method of administration
PANTOZOL Control 20 mg gastro-resistant tablets should not be chewed
or crushed, and should be
swallowed whole with liquid before a meal.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Co-administration of pantoprazole is not recommended with HIV protease
inhibitors for which
absorption is dependent on acidic intragastric pH such as atazanavir,
nelfinavir; due to significant
reduction in their bioavailability (see section 4.5).
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed to consult a doctor if:
•
Th
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 25-05-2023
产品特点 产品特点 保加利亚文 25-05-2023
公众评估报告 公众评估报告 保加利亚文 02-05-2013
资料单张 资料单张 西班牙文 25-05-2023
产品特点 产品特点 西班牙文 25-05-2023
公众评估报告 公众评估报告 西班牙文 02-05-2013
资料单张 资料单张 捷克文 25-05-2023
产品特点 产品特点 捷克文 25-05-2023
公众评估报告 公众评估报告 捷克文 02-05-2013
资料单张 资料单张 丹麦文 25-05-2023
产品特点 产品特点 丹麦文 25-05-2023
公众评估报告 公众评估报告 丹麦文 02-05-2013
资料单张 资料单张 德文 25-05-2023
产品特点 产品特点 德文 25-05-2023
公众评估报告 公众评估报告 德文 02-05-2013
资料单张 资料单张 爱沙尼亚文 25-05-2023
产品特点 产品特点 爱沙尼亚文 25-05-2023
公众评估报告 公众评估报告 爱沙尼亚文 02-05-2013
资料单张 资料单张 希腊文 25-05-2023
产品特点 产品特点 希腊文 25-05-2023
公众评估报告 公众评估报告 希腊文 02-05-2013
资料单张 资料单张 法文 25-05-2023
产品特点 产品特点 法文 25-05-2023
公众评估报告 公众评估报告 法文 02-05-2013
资料单张 资料单张 意大利文 25-05-2023
产品特点 产品特点 意大利文 25-05-2023
公众评估报告 公众评估报告 意大利文 02-05-2013
资料单张 资料单张 拉脱维亚文 25-05-2023
产品特点 产品特点 拉脱维亚文 25-05-2023
公众评估报告 公众评估报告 拉脱维亚文 02-05-2013
资料单张 资料单张 立陶宛文 25-05-2023
产品特点 产品特点 立陶宛文 25-05-2023
公众评估报告 公众评估报告 立陶宛文 02-05-2013
资料单张 资料单张 匈牙利文 25-05-2023
产品特点 产品特点 匈牙利文 25-05-2023
公众评估报告 公众评估报告 匈牙利文 02-05-2013
资料单张 资料单张 马耳他文 25-05-2023
产品特点 产品特点 马耳他文 25-05-2023
公众评估报告 公众评估报告 马耳他文 02-05-2013
资料单张 资料单张 荷兰文 25-05-2023
产品特点 产品特点 荷兰文 25-05-2023
公众评估报告 公众评估报告 荷兰文 02-05-2013
资料单张 资料单张 波兰文 25-05-2023
产品特点 产品特点 波兰文 25-05-2023
公众评估报告 公众评估报告 波兰文 02-05-2013
资料单张 资料单张 葡萄牙文 25-05-2023
产品特点 产品特点 葡萄牙文 25-05-2023
公众评估报告 公众评估报告 葡萄牙文 02-05-2013
资料单张 资料单张 罗马尼亚文 25-05-2023
产品特点 产品特点 罗马尼亚文 25-05-2023
公众评估报告 公众评估报告 罗马尼亚文 02-05-2013
资料单张 资料单张 斯洛伐克文 25-05-2023
产品特点 产品特点 斯洛伐克文 25-05-2023
公众评估报告 公众评估报告 斯洛伐克文 02-05-2013
资料单张 资料单张 斯洛文尼亚文 25-05-2023
产品特点 产品特点 斯洛文尼亚文 25-05-2023
公众评估报告 公众评估报告 斯洛文尼亚文 02-05-2013
资料单张 资料单张 芬兰文 25-05-2023
产品特点 产品特点 芬兰文 25-05-2023
公众评估报告 公众评估报告 芬兰文 02-05-2013
资料单张 资料单张 瑞典文 25-05-2023
产品特点 产品特点 瑞典文 25-05-2023
公众评估报告 公众评估报告 瑞典文 02-05-2013
资料单张 资料单张 挪威文 25-05-2023
产品特点 产品特点 挪威文 25-05-2023
资料单张 资料单张 冰岛文 25-05-2023
产品特点 产品特点 冰岛文 25-05-2023
资料单张 资料单张 克罗地亚文 25-05-2023
产品特点 产品特点 克罗地亚文 25-05-2023

搜索与此产品相关的警报